Literature DB >> 7044594

VP16-213 (etoposide). A critical review of its activity.

F Cavalli.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 7044594     DOI： 10.1007/bf00254526

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


× No keyword cloud information.
  32 in total

1.  PHASE I clinical trial of an oral solution of VP-16-213.

Authors:  N I Nissen; P Dombernowsky; H H Hansen; V Larsen
Journal:  Cancer Treat Rep       Date:  1976-07

2.  VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules.

Authors:  F Cavalli; R W Sonntag; F Jungi; H J Senn; K W Brunner
Journal:  Cancer Treat Rep       Date:  1978-03

Review 3.  VM 26 and VP 16-213: a comparative analysis.

Authors:  M Rozencweig; D D Von Hoff; J E Henney; F M Muggia
Journal:  Cancer       Date:  1977-07       Impact factor: 6.860

4.  Phase I clinical trial of a new antitumor agent, 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene- -D-glucopyranoside) (NSC-141540; VP-16-213).

Authors:  N I Nissen; V Larsen; H Pedersen; K Thomsen
Journal:  Cancer Chemother Rep       Date:  1972-12

5.  Analysis and interpretation of response rates for anticancer drugs.

Authors:  Y J Lee; R Catane; M Rozencweig; V H Bono; F M Muggia; R Simon; M J Staquet
Journal:  Cancer Treat Rep       Date:  1979 Nov-Dec

6.  A phase II study of oral VP-16-213 in non-seminomatous testicular cancer.

Authors:  F Cavalli; O Klepp; J Renard; M Röhrt; P Alberto
Journal:  Eur J Cancer       Date:  1981-02       Impact factor: 9.162

7.  VP-16-213 chemotherapy for advanced squamous cell carcinoma and adenocarcinoma of the lung.

Authors:  R T Eagan; J N Ingle; E T Creagan; S Frytak; L K Kvols; J Rubin; R T McMachon
Journal:  Cancer Treat Rep       Date:  1978-05

8.  Epipodophyllotoxin VP 16213 in treatment of acute leukaemias, haematosarcomas, and solid tumours.

Authors: 
Journal:  Br Med J       Date:  1973-07-28

Review 9.  Podophyllotoxin derivative VP 16-213.

Authors:  A M Arnold
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

Review 10.  Etoposide (VP-16-213).

Authors:  B F Issell; S T Crooke
Journal:  Cancer Treat Rev       Date:  1979-06       Impact factor: 12.111
View more
  12 in total

1.  Clinical pharmacology of intracarotid etoposide.

Authors:  N Savaraj; L G Feun; K Lu; S Wallace; W S Fields; T L Loo
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

2.  Antibacterial effect of etoposide in vitro.

Authors:  W Calame; R van der Waals; N Douwes-Idema; H Mattie; R van Furth
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

3.  The effect of dose on the bioavailability of oral etoposide.

Authors:  V J Harvey; M L Slevin; S P Joel; A Johnston; P F Wrigley
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

4.  Treatment of acute myelogenous leukemia in children.

Authors:  G Schellong; U Creutzig; J Ritter
Journal:  Med Oncol Tumor Pharmacother       Date:  1985

5.  Phase I study of high-dose cytosine arabinoside and etoposide in patients with advanced malignancies.

Authors:  B L Powell; H B Muss; R L Capizzi; M E Caponera; D R White; P J Zekan; J N Atkins; D V Jackson; F Richards; J B Craig
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 6.  The clinical pharmacology of etoposide and teniposide.

Authors:  P I Clark; M L Slevin
Journal:  Clin Pharmacokinet       Date:  1987-04       Impact factor: 6.447

7.  The effect of dose on the bioavailability of oral etoposide: confirmation of a clinically relevant observation.

Authors:  M L Slevin; S P Joel; R Whomsley; K Devenport; V J Harvey; R J Osborne; P F Wrigley
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

8.  Pharmacology of intrathecal VP-16-213 in dogs.

Authors:  N Savaraj; L G Feun; K Lu; K Gray; C Wang; T L Loo
Journal:  J Neurooncol       Date:  1992-07       Impact factor: 4.130

Review 9.  Schedule-dependent topoisomerase II-inhibiting drugs.

Authors:  S P Joel; M L Slevin
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 10.  Etoposide dosage and pharmacodynamics.

Authors:  S P Joel; R Shah; M L Slevin
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.